{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bendamustine+hcl&page=2", "query": { "intervention": "bendamustine hcl", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bendamustine+hcl&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T21:20:24.793Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02168140", "title": "CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Lymphocyte Depletion Hodgkin Lymphoma", "Adult Lymphocyte Predominant Hodgkin Lymphoma", "Adult Mixed Cellularity Hodgkin Lymphoma", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Adult Nodular Sclerosis Hodgkin Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Hepatosplenic T-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "T-cell Adult Acute Lymphoblastic Leukemia", "T-cell Large Granular Lymphocyte Leukemia" ], "interventions": [ { "name": "6,8-bis(benzylthio)octanoic acid", "type": "DRUG" }, { "name": "bendamustine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-09", "completion_date": "2022-09-15", "has_results": false, "last_update_posted_date": "2024-02-13", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 2, "location_summary": "Winston-Salem, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168140" }, { "nct_id": "NCT01286272", "title": "Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ann Arbor Stage III Grade 1 Follicular Lymphoma", "Ann Arbor Stage III Grade 2 Follicular Lymphoma", "Ann Arbor Stage III Grade 3 Follicular Lymphoma", "Ann Arbor Stage IV Grade 1 Follicular Lymphoma", "Ann Arbor Stage IV Grade 2 Follicular Lymphoma", "Ann Arbor Stage IV Grade 3 Follicular Lymphoma", "Grade 3a Follicular Lymphoma" ], "interventions": [ { "name": "Bendamustine Hydrochloride", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography with Radiolabeled Targeting Agent", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2011-04-28", "completion_date": "2025-09-02", "has_results": true, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 96, "location_summary": "La Jolla, California • St. Helena, California • Middletown, Connecticut + 70 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "St. Helena", "state": "California" }, { "city": "Middletown", "state": "Connecticut" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01286272" }, { "nct_id": "NCT04674813", "title": "A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-95266", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2021-02-24", "completion_date": "2025-12-22", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Duarte, California • San Francisco, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04674813" }, { "nct_id": "NCT02257242", "title": "Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Lymphoma, Small-Cell", "Waldenstrom Macroglobulinemia", "Lymphoma, B-Cell, Marginal Zone" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Vincristine sulfate liposome injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-05-10", "completion_date": "2020-11-18", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257242" }, { "nct_id": "NCT01232556", "title": "A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Inotuzumab ozogamicin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "rituximab + gemcitabine", "type": "DRUG" }, { "name": "rituximab +bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2011-04-04", "completion_date": "2014-03-28", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 82, "location_summary": "Burbank, California • Fresno, California • Los Angeles, California + 42 more", "locations": [ { "city": "Burbank", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232556" }, { "nct_id": "NCT01073163", "title": "Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cephalon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2010-02", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-04-24", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 36, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Fullerton, California + 32 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01073163" }, { "nct_id": "NCT07634471", "title": "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "MK-1045", "type": "BIOLOGICAL" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Rituximab biosimilar", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 960, "start_date": "2026-06-22", "completion_date": "2035-07-23", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 5, "location_summary": "Duarte, California • Lexington, Kentucky • Hackensack, New Jersey + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07634471" }, { "nct_id": "NCT06205290", "title": "A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell" ], "interventions": [ { "name": "Liso-cel", "type": "BIOLOGICAL" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-01-16", "completion_date": "2031-10-13", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Duarte, California • Sacramento, California + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boise", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT06205290" }, { "nct_id": "NCT01177683", "title": "Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sherif Farag, MB, BS", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2010-07", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2023-10-06", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 7, "location_summary": "Indianapolis, Indiana • Lafayette, Indiana • Wyoming, Michigan + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Wyoming", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177683" }, { "nct_id": "NCT01466153", "title": "A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "MEDI-551", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 183, "start_date": "2012-02-07", "completion_date": "2016-01-08", "has_results": true, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-09-23T21:20:24.793Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Burbank, California • La Jolla, California + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01466153" } ] }